Accessibility Menu
Ndt Pharmaceuticals logo

Ndt Pharmaceuticals(OTC) NDTP

Market Cap$96.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-99%
5 Year-51%
1 Year+702%
1 Month-7%
$0.49
+0.00%
+0.00Today
Ndt Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.492026-08-26
Ndt Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.75%USD 0.512026-08-19
1 month-6.69%USD 0.522026-07-27
3 month-16.62%USD 0.592026-05-28
Year to date-72.69%USD 1.792025-12-31
1 year+701.53%USD 0.062025-08-26
3 year-30.15%USD 0.702023-08-25
5 year-51.11%USD 1.002021-08-27
Since inception-99.21%USD 65.002011-10-21

Ndt Pharmaceuticals Financials at a Glance

Market Cap

$96.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$278.47K

Net Income (TTM)

-$1.02M

EPS (TTM)

-$0.01

P/E Ratio

-94.03

Dividend

$0.00

Beta (Volatility)

171.39 (High)

Price

$0.49

Volume

1,000

Open

$0.49

Previous Close

$0.49

Daily Range

$0.49 - $0.49

52-Week Range

$0.05 - $2.10

Estimated Earnings Date

Nov 14, 2007

NDTP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ndt Pharmaceuticals

NDT Pharmaceuticals Inc. is a biotechnology firm based in Vienna, Virginia, focused on developing innovative treatments for serious neurological conditions, particularly those resulting from traumatic brain injuries. The company aims to address significant unmet medical needs in the healthcare sector.

Products and Services
  • Development of therapies for traumatic brain injuries
  • Research initiatives targeting neurological disorders
  • Collaboration with healthcare professionals for treatment advancements
Growth Outlook
  • Recent quarterly revenue of $122,340 indicates potential market traction
  • Strong focus on R&D may lead to breakthrough therapies
  • Market cap of approximately $81.9 million suggests growth opportunities
Financial Highlights
  • Trailing twelve months (TTM) revenue of $122,340 shows initial sales
  • Current ratio of 4.09 indicates strong liquidity position
  • Net income for Q1 2026 reported at -$288,050, reflecting ongoing investment in growth
NDT Pharmaceuticals Inc. is positioned in the biotechnology sector, focusing on addressing critical neurological health issues. The company has made strides in its product development, as evidenced by its recent revenue figures. The strong liquidity position, indicated by a current ratio of 4.09, suggests that the company can meet its short-term obligations while continuing to invest in research and development. Despite reporting a net loss in the most recent quarter, the ongoing commitment to innovation and potential market opportunities may attract interest from investors looking for growth in the healthcare sector.
AI Generated • Aug 8, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Joseph C. Passalaqua

Website

www.ndtpharma.com

Headquarters

Vienna, VA 22182, US

NDTP Financials

Key Financial Metrics (TTM)

Gross Margin

-145.05%

Operating Margin

-365.55%

Net Income Margin

-366.41%

Return on Equity

-5.17%

Return on Capital

-49.46%

Return on Assets

-2.55%

Earnings Yield

-1.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$96.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

197.20M

Volume

1.00K

Avg. Volume

1.64K

Financials (TTM)

Gross Profit

-$403.90K

Operating Income

-$1.02M

EBITDA

-$631.79K

Operating Cash Flow

-$478.80K

Capital Expenditure

$7.00

Free Cash Flow

-$478.79K

Cash & ST Invst.

$80.85K

Total Debt

$701.00K

Ndt Pharmaceuticals Performance Analysis

Ndt Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Ndt Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-3027.6%
Ndt Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.00N/A
20242024-12-31USD -0.00-80.0%
20252025-12-31USD -0.00100.0%
Ndt Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30-140.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$156.13K

N/A

Gross Profit

-$364.21K

N/A

Gross Margin

-2.33%

N/A

Market Cap

$96.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$715.48K

-23797.3%

EBITDA

-$330.57K

-10941.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$80.85K

+12396.4%

Total Debt

$701.00K

N/A

Accounts Receivable

$535.30K

N/A

Inventory

$1.69M

N/A

Long Term Debt

$701.00K

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.55%

N/A

Return on Invested Capital

-2.56%

N/A

Free Cash Flow

-$469.81K

-21072.1%

Operating Cash Flow

-$469.81K

-21072.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AAWHAscend Wellness Holdings, Inc.
$0.43-3.43%
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%
SCNLFScancell Holdings plc
$0.14+0.00%
MLLCFMolecular Partners AG
$3.80+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$209.66-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.87-0.02%
BITOProShares Trust - ProShares Bitcoin ETF
$10.58-0.01%
INTCIntel
$88.24+0.01%

Questions About NDTP

What is the current price of Ndt Pharmaceuticals?

Ndt Pharmaceuticals is trading at $0.49 per share.

What is the 52-week range for Ndt Pharmaceuticals?

Over the past 52 weeks, Ndt Pharmaceuticals has traded between $0.05 and $2.10.

How much debt does Ndt Pharmaceuticals have?

As of the most recent reporting period, Ndt Pharmaceuticals reported total debt of $701.00K.

How much cash does Ndt Pharmaceuticals have on hand?

Ndt Pharmaceuticals reported $80.85K in cash and cash equivalents in its most recent financial results.

What is Ndt Pharmaceuticals’s dividend yield?

Ndt Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services